Erythema multiforme majusL51.1

Last updated on: 30.01.2025

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Acute, usually severe (up to max. 10% of KOF) mucocutaneous inflammatory syndrome characterized by a self-limited exanthema with characteristic, well-defined, target-like (disc-in-disc structure with heterogeneous ring formations, possibly also central blistering) and pronounced mucosal involvement (oral mucosa, conjunctiva, genital and anal mucosa). A transition to toxic epidermal necrolysis is excluded.

In the mycoplasma-induced rash and mucositis ( MIRM) variant, a predominance of enanthema, blistering, erosion and crusting can be observed, with the oral mucosa (94%), the eye region (82%) and the urogenital area (63%) being particularly affected. Infestation of the nasal introitus and anus is less common. Mucosal lesions are generally characterized as ulcerative or haemorrhagic and can cause symptoms. Involvement of the nose can manifest itself in the form of firm hemorrhagic crusts. Anal lesions can lead to pain during bowel movements.

EtiopathogenesisThis section has been translated automatically.

See below Erythema multiforme

In the case of erythema multiforme majus, which is characterized by extremity, the herpes simplex virus is a possible cause. In children, adolescents and young adults, Mycoplasma pneumoniae must be considered as a trigger with a high percentage. EM-majus can also be observed in combination of drugs with viral or bacterial infections (Wang S et al. 2022). In these cases, overlaps with other clinical pictures such as Stevens-Johnson syndrome or toxic epidermal necrolysis should be noted.

As with SJS, CD8+ driven, granzyme B-dependent, drug-specific cytotoxic activity against keratinocytes plays a significant role. It leads to keratinogenic apoptosis. Multiforme "scattering reactions" can also occur in allergic contact dermatitis (e.g. paraphenylenediamine in tattoos).

LocalizationThis section has been translated automatically.

Extremities (often accentuated on the extensor side), in children and adolescents (Mycoplasma pneumomiae as trigger) also trunk accentuation; involvement of the mucous membranes close to the surface (conjunctiva, labial and oral mucous membranes, anal and genital mucous membranes).

HistologyThis section has been translated automatically.

LiteratureThis section has been translated automatically.

  1. Creamer D et al. (2016) UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults.
  2. necrolysis in adults. J Plast Reconstr Aesthet Surg 69:e119-e153.
  3. Dodiuk-Gad RP et al. (2015) Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin DermatolPubMed PMID: 26481651.
  4. Gossart R et al. (2017) Fuchs Syndrome: Medical Treatment of 1 Case and Literature Review. Case Rep Dermatol 9:114-120.

  5. Hebert AA et al. (2004) Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol 50: 286-288
  6. Hertl M (2018) Severe cutaneous drug reactions. In: Braun-Falco`s Dermatology, Venereology Allergology G. Plewig et al. (ed.) Springer Verlag p 625
  7. Huang YC et al. (2012) The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal
  8. necrolysis: a systematic review and meta-analysis.Br J Dermatol: 167:424-432.
  9. Johnston GA et al (2002) Neonatal erythema multiforme major. Clin Exp Dermatol 27: 661-664
  10. Laffitte E et al. (2004) Severe Stevens-Johnson syndrome induced by contrast medium iopentol (Imagopaque). Br J Dermatol 150: 376-378
  11. Micheletti RG et al. (2018) Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol 138:2315-2321.
  12. Mockenhaupt M (2014) Severe drug-induced skin reactions. Dermatologist 65: 415-423
  13. Pereira FA et al (2007) Toxic epidermal necrolysis. J Am Acad Dermatol 56: 181-200
  14. Schmid MH, Elsner P (1999) An unusual hemorrhagic variant of Stevens-Johnson syndrome in an HIV-infected patient. Dermatology. 50: 52-55
  15. Schneck J et al. (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic
  16. epidermal necrolysis: A retrospective study on patients included in the
  17. prospective EuroSCAR Study.J Am Acad Dermatol 58: 33-40.
  18. Stevens AM, Johnson FC (1922) A new eruptive fever associated with stomatitis and ophthalmia: Report of two cases in children. Am J Dis Child 24: 526-533

Last updated on: 30.01.2025